| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.53 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.53. The average price that ABCL shares were previous bought at was USD 3.83934. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 39,035 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.54 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.54. The average price that ABUS shares were previous bought at was USD 3.83964. The current market price is 18.2% higher than average price they were purchased at. The value of the holding in ABUS has fallen by USD 14,175 compared to the previous valuation of Arbutus Biopharma Corp |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 26.6 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 26.6. The average price that ACAD shares were previous bought at was USD 22.0973. The current market price is 20.4% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 40,955 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 2.95 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 2.95. The average price that ACIU shares were previous bought at was USD 2.56758. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in ACIU has increased by USD 728 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 64.13 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 64.13. The average price that ACLX shares were previous bought at was USD 72.202. The current market price is -11.2% lower than average price they were purchased at. The value of the holding in ACLX has fallen by USD 24,301 compared to the previous valuation of Arcellx Inc |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 18.81 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 18.81. The average price that ADMA shares were previous bought at was USD 17.8309. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in ADMA has fallen by USD 3,511 compared to the previous valuation of ADMA Biologics Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 16.5 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 16.5. The average price that ADPT shares were previous bought at was USD 13.4506. The current market price is 22.7% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 43,007 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AGIO - Agios Pharm | HOLD | 0 @ USD 24.73 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 24.73. The average price that AGIO shares were previous bought at was USD 33.9293. The current market price is -27.1% lower than average price they were purchased at. The value of the holding in AGIO has fallen by USD 31,459 compared to the previous valuation of Agios Pharm |
| ALEC - Alector Inc | HOLD | 0 @ USD 1.39 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 1.39. The average price that ALEC shares were previous bought at was USD 1.70509. The current market price is -18.5% lower than average price they were purchased at. The value of the holding in ALEC has increased by USD 3,100 compared to the previous valuation of Alector Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 27.81 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 27.81. The average price that ALKS shares were previous bought at was USD 30.05. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 28,141 compared to the previous valuation of Alkermes Plc |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.42 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.42. The average price that ALLO shares were previous bought at was USD 1.34689. The current market price is 5.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 396.04 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 396.04. The average price that ALNY shares were previous bought at was USD 395.411. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 378,607 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 5.04999 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 5.04999. The average price that ALT shares were previous bought at was USD 5.14417. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in ALT has fallen by USD 2,477 compared to the previous valuation of Altitude Group Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 324.42 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 324.42. The average price that AMGN shares were previous bought at was USD 299.477. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 338,045 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 11.92 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 11.92. The average price that AMLX shares were previous bought at was USD 8.41455. The current market price is 41.7% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 3,234 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AMPH - Amphastar P | HOLD | 0 @ USD 26.5 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 26.5. The average price that AMPH shares were previous bought at was USD 25.8292. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in AMPH has increased by USD 14,488 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 12.64 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 12.64. The average price that AMRX shares were previous bought at was USD 9.64518. The current market price is 31.0% higher than average price they were purchased at. The value of the holding in AMRX has increased by USD 71,737 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 47.53 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 47.53. The average price that ANAB shares were previous bought at was USD 28.5512. The current market price is 66.5% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 37,311 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 82.83 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 82.83. The average price that ANIP shares were previous bought at was USD 74.884. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in ANIP has increased by USD 7,815 compared to the previous valuation of ANI Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 77.35 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 77.35. The average price that APGE shares were previous bought at was USD 52.0132. The current market price is 48.7% higher than average price they were purchased at. The value of the holding in APGE has increased by USD 63,153 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 24.48 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 24.48. The average price that APLS shares were previous bought at was USD 21.1068. The current market price is 16.0% higher than average price they were purchased at. The value of the holding in APLS has fallen by USD 66,985 compared to the previous valuation of Apellis Pharmaceuticals Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.42999 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.42999. The average price that ARCT shares were previous bought at was USD 12.4562. The current market price is -48.4% lower than average price they were purchased at. The value of the holding in ARCT has fallen by USD 1,870 compared to the previous valuation of Arcturus Therapeutics Holdings Inc |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 5.68 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 5.68. The average price that ARDX shares were previous bought at was USD 4.92786. The current market price is 15.3% higher than average price they were purchased at. The value of the holding in ARDX has fallen by USD 19,233 compared to the previous valuation of Ardelyx Inc |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 847.05 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 847.05. The average price that ARGX shares were previous bought at was USD 715.907. The current market price is 18.3% higher than average price they were purchased at. The value of the holding in ARGX has fallen by USD 339,465 compared to the previous valuation of argenx NV ADR |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 27.78 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 27.78. The average price that ARQT shares were previous bought at was USD 20.1616. The current market price is 37.8% higher than average price they were purchased at. The value of the holding in ARQT has fallen by USD 49,619 compared to the previous valuation of Arcutis Biotherapeutics Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.28 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.28. The average price that ARVN shares were previous bought at was USD 9.94644. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in ARVN has fallen by USD 24,706 compared to the previous valuation of Arvinas Inc |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 66.47 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 66.47. The average price that ARWR shares were previous bought at was USD 30.2525. The current market price is 119.7% higher than average price they were purchased at. The value of the holding in ARWR has increased by USD 170,290 compared to the previous valuation of Arrowhead Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 199.8 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 199.8. The average price that ASND shares were previous bought at was USD 186.345. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in ASND has fallen by USD 135,845 compared to the previous valuation of Ascendis Pharma AS |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 15.91 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 15.91. The average price that AUPH shares were previous bought at was USD 11.3392. The current market price is 40.3% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 11,870 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.57 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.57. The average price that AUTL shares were previous bought at was USD 1.74199. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in AUTL has increased by USD 1,583 compared to the previous valuation of Autolus Therapeutics Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 21.42 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 21.42. The average price that AVDL shares were previous bought at was USD 13.7243. The current market price is 56.1% higher than average price they were purchased at. The value of the holding in AVDL has increased by USD 1,407 compared to the previous valuation of Avadel Pharmaceuticals PLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.12999 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.12999. The average price that AVIR shares were previous bought at was USD 3.25167. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in AVIR has fallen by USD 3,056 compared to the previous valuation of Atea Pharmaceuticals Inc |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 3.89 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 3.89. The average price that AVXL shares were previous bought at was USD 8.07409. The current market price is -51.8% lower than average price they were purchased at. The value of the holding in AVXL has fallen by USD 1,876 compared to the previous valuation of Anavex Life Sciences Corp |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 147 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 147. The average price that AXSM shares were previous bought at was USD 123.568. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 36,804 compared to the previous valuation of Axsome Therapeutics Inc |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 90.61 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 90.61. The average price that AZN shares were previous bought at was USD 78.7875. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in AZN has increased by USD 287,088 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 74.14 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 74.14. The average price that BBIO shares were previous bought at was USD 52.1831. The current market price is 42.1% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 16,981 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.29 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.29. The average price that BCRX shares were previous bought at was USD 8.03142. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 25,301 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 6.77 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 6.77. The average price that BCYC shares were previous bought at was USD 8.15555. The current market price is -17.0% lower than average price they were purchased at. The value of the holding in BCYC has fallen by USD 6,212 compared to the previous valuation of Bicycle Therapeutics Ltd |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 26.17 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 26.17. The average price that BEAM shares were previous bought at was USD 21.9707. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 42,907 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 169.91 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 169.91. The average price that BIIB shares were previous bought at was USD 149.071. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 237,344 compared to the previous valuation of Biogen Inc |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.35 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.35. The average price that BMEA shares were previous bought at was USD 1.51319. The current market price is -10.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 51.95 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 51.95. The average price that BMRN shares were previous bought at was USD 57.0929. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in BMRN has increased by USD 21,290 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BNTX - BioNTech SE | HOLD | 0 @ USD 91.46 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 91.46. The average price that BNTX shares were previous bought at was USD 103.084. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in BNTX has fallen by USD 10,439 compared to the previous valuation of BioNTech SE |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 9.98001 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 9.98001. The average price that CGEM shares were previous bought at was USD 8.57694. The current market price is 16.4% higher than average price they were purchased at. The value of the holding in CGEM has increased by USD 17,323 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 38 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 38. The average price that CGON shares were previous bought at was USD 33.0567. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 35,357 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 24.85 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 24.85. The average price that CNTA shares were previous bought at was USD 19.5396. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in CNTA has fallen by USD 9,270 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 37.9 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 37.9. The average price that COGT shares were previous bought at was USD 18.29. The current market price is 107.2% higher than average price they were purchased at. The value of the holding in COGT has fallen by USD 160,605 compared to the previous valuation of Cogent Biosciences Inc |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 49.33 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 49.33. The average price that COLL shares were previous bought at was USD 35.6563. The current market price is 38.3% higher than average price they were purchased at. The value of the holding in COLL has increased by USD 9,814 compared to the previous valuation of Collegium Pharmaceutical Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 45.14 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 45.14. The average price that CRNX shares were previous bought at was USD 37.9409. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in CRNX has fallen by USD 178,449 compared to the previous valuation of Crinetics Pharmaceuticals Inc |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 54.84 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 54.84. The average price that CRSP shares were previous bought at was USD 53.3058. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in CRSP has increased by USD 6,731 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.6 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.6. The average price that CSTL shares were previous bought at was USD 26.271. The current market price is 50.7% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 1,266 compared to the previous valuation of Castle Biosciences Inc |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 62.2 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 62.2. The average price that CYTK shares were previous bought at was USD 48.9512. The current market price is 27.1% higher than average price they were purchased at. The value of the holding in CYTK has increased by USD 209,735 compared to the previous valuation of Cytokinetics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.97 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.97. The average price that DAWN shares were previous bought at was USD 7.72272. The current market price is 29.1% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 89,292 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 16.77 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 16.77. The average price that DNLI shares were previous bought at was USD 16.1568. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in DNLI has fallen by USD 4,347 compared to the previous valuation of Denali Therapeutics Inc |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.87 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.87. The average price that DVAX shares were previous bought at was USD 10.6546. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 6,805 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 18.55 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 18.55. The average price that DYN shares were previous bought at was USD 14.4536. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 36,658 compared to the previous valuation of Dyne Therapeutics Inc |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 18.55 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 18.55. The average price that DYN shares were previous bought at was USD 14.4536. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 36,658 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.35 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.35. The average price that EDIT shares were previous bought at was USD 2.61551. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in EDIT has fallen by USD 1,398 compared to the previous valuation of Editas Medicine Inc |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 16.68 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 16.68. The average price that ELVN shares were previous bought at was USD 20.5559. The current market price is -18.9% lower than average price they were purchased at. The value of the holding in ELVN has increased by USD 28,317 compared to the previous valuation of Enliven Therapeutics Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 7.18 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 7.18. The average price that EOLS shares were previous bought at was USD 8.56985. The current market price is -16.2% lower than average price they were purchased at. The value of the holding in EOLS has increased by USD 5,096 compared to the previous valuation of Evolus Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ERAS - Erasca Inc | HOLD | 0 @ USD 3.6 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 3.6. The average price that ERAS shares were previous bought at was USD 2.02691. The current market price is 77.6% higher than average price they were purchased at. The value of the holding in ERAS has fallen by USD 8,811 compared to the previous valuation of Erasca Inc |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 21.15 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 21.15. The average price that EWTX shares were previous bought at was USD 17.9438. The current market price is 17.9% higher than average price they were purchased at. The value of the holding in EWTX has fallen by USD 90,748 compared to the previous valuation of Edgewise Therapeutics Inc |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 42.57 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 42.57. The average price that EXEL shares were previous bought at was USD 41.6794. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 113,422 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.05 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.05. The average price that FATE shares were previous bought at was USD 1.1465. The current market price is -8.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 10.89 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 10.89. The average price that FOLD shares were previous bought at was USD 8.09081. The current market price is 34.6% higher than average price they were purchased at. The value of the holding in FOLD has fallen by USD 25,172 compared to the previous valuation of Amicus Therapeutics Inc |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 16.61 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 16.61. The average price that FTRE shares were previous bought at was USD 8.4198. The current market price is 97.3% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 27,675 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.34 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.34. The average price that GERN shares were previous bought at was USD 1.43749. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in GERN has fallen by USD 27,529 compared to the previous valuation of Geron Corporation |
| GH - Guardant Health Inc | HOLD | 0 @ USD 97.1 | USD 0 | The current share valuation price of GH based on adjusted close was USD 97.1. The average price that GH shares were previous bought at was USD 68.6525. The current market price is 41.4% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 34,071 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 121.47 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 121.47. The average price that GILD shares were previous bought at was USD 115.871. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 59,561 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 31.63 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.63. The average price that GLPG shares were previous bought at was USD 29.7426. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,098 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 31.63 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.63. The average price that GLPG shares were previous bought at was USD 29.7426. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,098 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 31.5 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 31.5. The average price that GMAB shares were previous bought at was USD 25.5228. The current market price is 23.4% higher than average price they were purchased at. The value of the holding in GMAB has fallen by USD 6,376 compared to the previous valuation of Genmab AS |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 62.45 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 62.45. The average price that GPCR shares were previous bought at was USD 27.9063. The current market price is 123.8% higher than average price they were purchased at. The value of the holding in GPCR has increased by USD 108,915 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 88.315 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 88.315. The average price that GRAL shares were previous bought at was USD 63.9902. The current market price is 38.0% higher than average price they were purchased at. The value of the holding in GRAL has increased by USD 64,920 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 8.92 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 8.92. The average price that GRFS shares were previous bought at was USD 9.21387. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in GRFS has increased by USD 885 compared to the previous valuation of Grifols SA ADR however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 65.11 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 65.11. The average price that HALO shares were previous bought at was USD 61.4961. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 56,890 compared to the previous valuation of Halozyme Therapeutics Inc |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 13.35 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 13.35. The average price that HCM shares were previous bought at was USD 15.1543. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in HCM has increased by USD 2,080 compared to the previous valuation of HUTCHMED China Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 13.35 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 13.35. The average price that HCM shares were previous bought at was USD 15.1543. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in HCM has increased by USD 2,080 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 37.47 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 37.47. The average price that HRMY shares were previous bought at was USD 33.4492. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 56,102 compared to the previous valuation of Harmony Biosciences Holdings |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 44.56 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 44.56. The average price that HROW shares were previous bought at was USD 37.118. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in HROW has increased by USD 4,750 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.11 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.11. The average price that HUMA shares were previous bought at was USD 1.98857. The current market price is -44.2% lower than average price they were purchased at. The value of the holding in HUMA has increased by USD 4,745 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.09 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.09. The average price that IBRX shares were previous bought at was USD 2.6304. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 13,896 compared to the previous valuation of Immunitybio Inc |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 33.26 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 33.26. The average price that IDYA shares were previous bought at was USD 26.2583. The current market price is 26.7% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 30,443 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 130.51 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 130.51. The average price that ILMN shares were previous bought at was USD 105.819. The current market price is 23.3% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 107,931 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 35.9 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 35.9. The average price that IMCR shares were previous bought at was USD 34.3094. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in IMCR has increased by USD 2,385 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 26.18 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 26.18. The average price that IMVT shares were previous bought at was USD 19.1832. The current market price is 36.5% higher than average price they were purchased at. The value of the holding in IMVT has fallen by USD 102,860 compared to the previous valuation of Immunovant Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 97.31 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 97.31. The average price that INCY shares were previous bought at was USD 81.6071. The current market price is 19.2% higher than average price they were purchased at. The value of the holding in INCY has fallen by USD 46,190 compared to the previous valuation of Incyte Corporation |
| INSM - Insmed Inc | HOLD | 0 @ USD 166.55 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 166.55. The average price that INSM shares were previous bought at was USD 141.595. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in INSM has fallen by USD 4,985,746 compared to the previous valuation of Insmed Inc |
| INVA - Innoviva Inc | HOLD | 0 @ USD 20.07 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 20.07. The average price that INVA shares were previous bought at was USD 19.6062. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in INVA has increased by USD 953 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 77.63 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 77.63. The average price that IONS shares were previous bought at was USD 56.8592. The current market price is 36.5% higher than average price they were purchased at. The value of the holding in IONS has increased by USD 64,651 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.46 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.46. The average price that IOVA shares were previous bought at was USD 2.3941. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in IOVA has fallen by USD 15,457 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IRON - Ironveld Plc | HOLD | 0 @ USD 90.44 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 90.44. The average price that IRON shares were previous bought at was USD 66.217. The current market price is 36.6% higher than average price they were purchased at. The value of the holding in IRON has increased by USD 75,555 compared to the previous valuation of Ironveld Plc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 3.26 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 3.26. The average price that IRWD shares were previous bought at was USD 2.34928. The current market price is 38.8% higher than average price they were purchased at. The value of the holding in IRWD has fallen by USD 13,913 compared to the previous valuation of Ironwood Pharmaceuticals Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 14.04 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 14.04. The average price that JANX shares were previous bought at was USD 26.2528. The current market price is -46.5% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 2,612 compared to the previous valuation of Janux Therapeutics Inc |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 166 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 166. The average price that JAZZ shares were previous bought at was USD 135.407. The current market price is 22.6% higher than average price they were purchased at. The value of the holding in JAZZ has increased by USD 48,769 compared to the previous valuation of Jazz Pharmaceuticals PLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 15 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 15. The average price that KALV shares were previous bought at was USD 13.5733. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in KALV has increased by USD 5,835 compared to the previous valuation of Kalvista Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42. The average price that KNSA shares were previous bought at was USD 32.8049. The current market price is 28.0% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 16,934 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 20.13 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 20.13. The average price that KROS shares were previous bought at was USD 15.8434. The current market price is 27.1% higher than average price they were purchased at. The value of the holding in KROS has fallen by USD 21,772 compared to the previous valuation of Keros Therapeutics Inc |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 233.37 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 233.37. The average price that KRYS shares were previous bought at was USD 177.51. The current market price is 31.5% higher than average price they were purchased at. The value of the holding in KRYS has fallen by USD 51,978 compared to the previous valuation of Krystal Biotech Inc |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.85 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.85. The average price that KURA shares were previous bought at was USD 8.28389. The current market price is 18.9% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 21,655 compared to the previous valuation of Kura Oncology Inc |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 79.63 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 79.63. The average price that KYMR shares were previous bought at was USD 52.5563. The current market price is 51.5% higher than average price they were purchased at. The value of the holding in KYMR has fallen by USD 129,179 compared to the previous valuation of Kymera Therapeutics Inc |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 21.28 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 21.28. The average price that LEGN shares were previous bought at was USD 32.7402. The current market price is -35.0% lower than average price they were purchased at. The value of the holding in LEGN has fallen by USD 8,611 compared to the previous valuation of Legend Biotech Corp |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 198.41 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 198.41. The average price that LGND shares were previous bought at was USD 149.15. The current market price is 33.0% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 55,051 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 1.18 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 1.18. The average price that LXRX shares were previous bought at was USD 1.15741. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in LXRX has increased by USD 8,241 compared to the previous valuation of Lexicon Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 32.38 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 32.38. The average price that LYEL shares were previous bought at was USD 8.48496. The current market price is 281.6% higher than average price they were purchased at. The value of the holding in LYEL has increased by USD 4,327 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 544.41 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 544.41. The average price that MDGL shares were previous bought at was USD 411.281. The current market price is 32.4% higher than average price they were purchased at. The value of the holding in MDGL has fallen by USD 29,277 compared to the previous valuation of Madrigal Pharmaceuticals Inc |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 560.21 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 560.21. The average price that MEDP shares were previous bought at was USD 445.12. The current market price is 25.9% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 65,221 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.56999 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.56999. The average price that MGNX shares were previous bought at was USD 1.52908. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in MGNX has fallen by USD 1,800 compared to the previous valuation of MacroGenics Inc |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 7.96001 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 7.96001. The average price that MGTX shares were previous bought at was USD 7.4402. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in MGTX has fallen by USD 8,773 compared to the previous valuation of MeiraGTx Holdings PLC |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 70.28 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 70.28. The average price that MIRM shares were previous bought at was USD 59.3746. The current market price is 18.4% higher than average price they were purchased at. The value of the holding in MIRM has increased by USD 47,259 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 37 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 37. The average price that MLYS shares were previous bought at was USD 24.5678. The current market price is 50.6% higher than average price they were purchased at. The value of the holding in MLYS has fallen by USD 988 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.97 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.97. The average price that MNKD shares were previous bought at was USD 4.95458. The current market price is 20.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 12.54 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 12.54. The average price that MNMD shares were previous bought at was USD 9.5334. The current market price is 31.5% higher than average price they were purchased at. The value of the holding in MNMD has increased by USD 23,060 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 30.95 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 30.95. The average price that MRNA shares were previous bought at was USD 28.1569. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in MRNA has increased by USD 126,541 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 29.0999 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 29.0999. The average price that MRSN shares were previous bought at was USD 1.31897. The current market price is 2,106.3% higher than average price they were purchased at. The value of the holding in MRSN has increased by USD 137 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.52 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.52. The average price that MRVI shares were previous bought at was USD 2.94024. The current market price is 19.7% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 6,814 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 1.52001 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 1.52001. The average price that MXCT shares were previous bought at was USD 1.99956. The current market price is -24.0% lower than average price they were purchased at. The value of the holding in MXCT has increased by USD 2,341 compared to the previous valuation of MaxCyte Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 141.84 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 141.84. The average price that NBIX shares were previous bought at was USD 135.725. The current market price is 4.5% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 10,266 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 18.01 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 18.01. The average price that NRIX shares were previous bought at was USD 13.2326. The current market price is 36.1% higher than average price they were purchased at. The value of the holding in NRIX has fallen by USD 11,661 compared to the previous valuation of Nurix Therapeutics Inc |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 8.88 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 8.88. The average price that NTLA shares were previous bought at was USD 11.4968. The current market price is -22.8% lower than average price they were purchased at. The value of the holding in NTLA has increased by USD 7,097 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 101.41 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 101.41. The average price that NUVL shares were previous bought at was USD 88.7259. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 7,875 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.68 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.68. The average price that NVAX shares were previous bought at was USD 7.2023. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in NVAX has increased by USD 17,676 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.68 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.68. The average price that NVAX shares were previous bought at was USD 7.2023. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in NVAX has increased by USD 17,676 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.56 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.56. The average price that NVCR shares were previous bought at was USD 15.3912. The current market price is -18.4% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 18,644 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 2.01 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 2.01. The average price that OABI shares were previous bought at was USD 1.88823. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in OABI has fallen by USD 4,498 compared to the previous valuation of OmniAb Inc. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 12.98 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 12.98. The average price that OCUL shares were previous bought at was USD 10.7426. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in OCUL has fallen by USD 95,793 compared to the previous valuation of Ocular Therapeutix Inc |
| OKUR - OKUR | HOLD | 0 @ USD 3.10997 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 3.10997. The average price that OKUR shares were previous bought at was USD 5.56734. The current market price is -44.1% lower than average price they were purchased at. The value of the holding in OKUR has increased by USD 1,505 compared to the previous valuation of OKUR however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 30.81 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 30.81. The average price that OLMA shares were previous bought at was USD 11.1658. The current market price is 175.9% higher than average price they were purchased at. The value of the holding in OLMA has fallen by USD 90,912 compared to the previous valuation of Olema Pharmaceuticals Inc |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 8.08501 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 8.08501. The average price that ORIC shares were previous bought at was USD 10.6475. The current market price is -24.1% lower than average price they were purchased at. The value of the holding in ORIC has fallen by USD 9,505 compared to the previous valuation of Oric Pharmaceuticals Inc |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.88 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.88. The average price that PACB shares were previous bought at was USD 1.69829. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 11,508 compared to the previous valuation of Pacific Biosciences of California |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 40.41 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 40.41. The average price that PAHC shares were previous bought at was USD 31.5119. The current market price is 28.2% higher than average price they were purchased at. The value of the holding in PAHC has fallen by USD 2,769 compared to the previous valuation of Phibro Animal Health Corporation |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 25.88 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 25.88. The average price that PCRX shares were previous bought at was USD 23.8626. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in PCRX has fallen by USD 21,820 compared to the previous valuation of Pacira BioSciences, Inc. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 43.71 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 43.71. The average price that PCVX shares were previous bought at was USD 45.0066. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in PCVX has increased by USD 62,471 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PGEN - Precigen Inc | HOLD | 0 @ USD 4.17 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 4.17. The average price that PGEN shares were previous bought at was USD 2.70172. The current market price is 54.3% higher than average price they were purchased at. The value of the holding in PGEN has increased by USD 42,015 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 16.28 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 16.28. The average price that PHAT shares were previous bought at was USD 10.5456. The current market price is 54.4% higher than average price they were purchased at. The value of the holding in PHAT has increased by USD 48,313 compared to the previous valuation of Phathom Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.21 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.21. The average price that PLRX shares were previous bought at was USD 1.47912. The current market price is -18.2% lower than average price they were purchased at. The value of the holding in PLRX has fallen by USD 424 compared to the previous valuation of Pliant Therapeutics Inc |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 269.26 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 269.26. The average price that PRAX shares were previous bought at was USD 98.2598. The current market price is 174.0% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 53,016 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 3.6 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 3.6. The average price that PRME shares were previous bought at was USD 4.34727. The current market price is -17.2% lower than average price they were purchased at. The value of the holding in PRME has fallen by USD 17,782 compared to the previous valuation of Prime Medicine, Inc. Common Stock |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 9.38 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 9.38. The average price that PRTA shares were previous bought at was USD 9.45542. The current market price is -0.8% lower than average price they were purchased at. The value of the holding in PRTA has fallen by USD 1,995 compared to the previous valuation of Prothena Corporation plc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 74.59 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 74.59. The average price that PTCT shares were previous bought at was USD 61.273. The current market price is 21.7% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 20,581 compared to the previous valuation of PTC Therapeutics Inc |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 85.79 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 85.79. The average price that PTGX shares were previous bought at was USD 64.886. The current market price is 32.2% higher than average price they were purchased at. The value of the holding in PTGX has fallen by USD 163,729 compared to the previous valuation of Protagonist Therapeutics Inc |
| QURE - Uniqure NV | HOLD | 0 @ USD 23.93 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 23.93. The average price that QURE shares were previous bought at was USD 23.4439. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in QURE has increased by USD 36,051 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RARE - Ultragenyx | HOLD | 0 @ USD 32.84 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 32.84. The average price that RARE shares were previous bought at was USD 35.8581. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 26,300 compared to the previous valuation of Ultragenyx |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 32.84 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 32.84. The average price that RARE shares were previous bought at was USD 35.8581. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 26,300 compared to the previous valuation of WISETFWTMRARETFP |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.23 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.23. The average price that RCKT shares were previous bought at was USD 4.6478. The current market price is -30.5% lower than average price they were purchased at. The value of the holding in RCKT has fallen by USD 3,112 compared to the previous valuation of Rocket Pharmaceuticals Inc |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 748.71 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 748.71. The average price that REGN shares were previous bought at was USD 649.194. The current market price is 15.3% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 82,472 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 9.69 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 9.69. The average price that REPL shares were previous bought at was USD 9.15336. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in REPL has increased by USD 1,741 compared to the previous valuation of Replimune Group Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.51 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.51. The average price that RGNX shares were previous bought at was USD 10.0406. The current market price is 34.6% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 12,970 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.13 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.13. The average price that RLAY shares were previous bought at was USD 4.90988. The current market price is 65.6% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 12,514 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 72.135 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 72.135. The average price that RNA shares were previous bought at was USD 46.9429. The current market price is 53.7% higher than average price they were purchased at. The value of the holding in RNA has increased by USD 25,238 compared to the previous valuation of Avidity Biosciences Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 21.79 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 21.79. The average price that ROIV shares were previous bought at was USD 15.2175. The current market price is 43.2% higher than average price they were purchased at. The value of the holding in ROIV has fallen by USD 458,089 compared to the previous valuation of Roivant Sciences Ltd |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.43 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.43. The average price that RPRX shares were previous bought at was USD 36.708. The current market price is 4.7% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 38,345 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 75.96 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 75.96. The average price that RVMD shares were previous bought at was USD 50.1446. The current market price is 51.5% higher than average price they were purchased at. The value of the holding in RVMD has fallen by USD 107,936 compared to the previous valuation of Revolution Medicines Inc |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.44 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.44. The average price that RXRX shares were previous bought at was USD 5.51461. The current market price is -19.5% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 75,651 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 111.73 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 111.73. The average price that RYTM shares were previous bought at was USD 83.781. The current market price is 33.4% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 6,391 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.5 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.5. The average price that SANA shares were previous bought at was USD 3.49243. The current market price is 28.9% higher than average price they were purchased at. The value of the holding in SANA has fallen by USD 53,382 compared to the previous valuation of Sana Biotechnology Inc |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.31 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.31. The average price that SIGA shares were previous bought at was USD 6.6331. The current market price is -4.9% lower than average price they were purchased at. The value of the holding in SIGA has fallen by USD 3,583 compared to the previous valuation of SIGA Technologies Inc |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 17.04 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 17.04. The average price that SMMT shares were previous bought at was USD 20.4764. The current market price is -16.8% lower than average price they were purchased at. The value of the holding in SMMT has increased by USD 16,487 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 20.23 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 20.23. The average price that SNDX shares were previous bought at was USD 14.0596. The current market price is 43.9% higher than average price they were purchased at. The value of the holding in SNDX has fallen by USD 9,053 compared to the previous valuation of Syndax Pharmaceuticals Inc |
| SNY - Sanofi ADR | HOLD | 0 @ USD 47.99 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 47.99. The average price that SNY shares were previous bought at was USD 49.8689. The current market price is -3.8% lower than average price they were purchased at. The value of the holding in SNY has fallen by USD 29,795 compared to the previous valuation of Sanofi ADR |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 9.82001 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 9.82001. The average price that SPRY shares were previous bought at was USD 12.4193. The current market price is -20.9% lower than average price they were purchased at. The value of the holding in SPRY has fallen by USD 18,822 compared to the previous valuation of Silverback Therapeutics Inc |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 20.34 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 20.34. The average price that SRPT shares were previous bought at was USD 30.0903. The current market price is -32.4% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 58,245 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 42.93 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 42.93. The average price that SRRK shares were previous bought at was USD 36.9163. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in SRRK has fallen by USD 76,204 compared to the previous valuation of Scholar Rock Holding Corp |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.93 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.93. The average price that STOK shares were previous bought at was USD 19.6492. The current market price is 62.5% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 37,691 compared to the previous valuation of Stoke Therapeutics Inc |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 8.93007 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 8.93007. The average price that STRO shares were previous bought at was USD 1.03176. The current market price is 765.5% higher than average price they were purchased at. The value of the holding in STRO has fallen by USD 1,106 compared to the previous valuation of Sutro Biopharma |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 49.28 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 49.28. The average price that SUPN shares were previous bought at was USD 39.4199. The current market price is 25.0% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 21,942 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| SVRA - Savara Inc | HOLD | 0 @ USD 6.06 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 6.06. The average price that SVRA shares were previous bought at was USD 3.7196. The current market price is 62.9% higher than average price they were purchased at. The value of the holding in SVRA has fallen by USD 6,246 compared to the previous valuation of Savara Inc |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 33.47 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 33.47. The average price that SYRE shares were previous bought at was USD 21.6111. The current market price is 54.9% higher than average price they were purchased at. The value of the holding in SYRE has increased by USD 18,500 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 77.48 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 77.48. The average price that TARS shares were previous bought at was USD 56.6878. The current market price is 36.7% higher than average price they were purchased at. The value of the holding in TARS has fallen by USD 9,027 compared to the previous valuation of Tarsus Pharmaceuticals Inc |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 18.18 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 18.18. The average price that TBPH shares were previous bought at was USD 13.5517. The current market price is 34.2% higher than average price they were purchased at. The value of the holding in TBPH has increased by USD 9,873 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 39.82 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 39.82. The average price that TERN shares were previous bought at was USD 11.663. The current market price is 241.4% higher than average price they were purchased at. The value of the holding in TERN has fallen by USD 140,102 compared to the previous valuation of Tern Plc |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 8.46 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 8.46. The average price that TNGX shares were previous bought at was USD 7.2819. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in TNGX has fallen by USD 25,812 compared to the previous valuation of Tango Therapeutics Inc |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 10.96 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 10.96. The average price that TRDA shares were previous bought at was USD 8.23347. The current market price is 33.1% higher than average price they were purchased at. The value of the holding in TRDA has fallen by USD 7,743 compared to the previous valuation of Entrada Therapeutics Inc |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 5.45 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 5.45. The average price that TSHA shares were previous bought at was USD 3.26801. The current market price is 66.8% higher than average price they were purchased at. The value of the holding in TSHA has increased by USD 1,981 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 34.49 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 34.49. The average price that TVTX shares were previous bought at was USD 24.1834. The current market price is 42.6% higher than average price they were purchased at. The value of the holding in TVTX has increased by USD 39,685 compared to the previous valuation of Travere Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.92 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.92. The average price that TWST shares were previous bought at was USD 34.6802. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 9,544 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 16 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16. The average price that TXG shares were previous bought at was USD 13.611. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 20,951 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 16 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16. The average price that TXG shares were previous bought at was USD 13.611. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 20,951 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 21.72 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 21.72. The average price that URGN shares were previous bought at was USD 17.0229. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in URGN has fallen by USD 31,273 compared to the previous valuation of UroGen Pharma Ltd |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 507 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 507. The average price that UTHR shares were previous bought at was USD 380.392. The current market price is 33.3% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 131,718 compared to the previous valuation of United Therapeutics Corporation |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 36.16 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 36.16. The average price that VCEL shares were previous bought at was USD 39.9007. The current market price is -9.4% lower than average price they were purchased at. The value of the holding in VCEL has fallen by USD 9,121 compared to the previous valuation of Vericel Corp Ord |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 42.04 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 42.04. The average price that VCYT shares were previous bought at was USD 34.9468. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 9,879 compared to the previous valuation of Veracyte Inc |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 47.69 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 47.69. The average price that VERA shares were previous bought at was USD 30.2541. The current market price is 57.6% higher than average price they were purchased at. The value of the holding in VERA has fallen by USD 39,840 compared to the previous valuation of Vera Therapeutics Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.93 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.93. The average price that VIR shares were previous bought at was USD 5.92884. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in VIR has fallen by USD 21,031 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.93 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.93. The average price that VIR shares were previous bought at was USD 5.92884. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in VIR has fallen by USD 21,031 compared to the previous valuation of Vidrala S.A |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 6.67 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 6.67. The average price that VNDA shares were previous bought at was USD 4.93606. The current market price is 35.1% higher than average price they were purchased at. The value of the holding in VNDA has fallen by USD 6,994 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 447.38 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 447.38. The average price that VRTX shares were previous bought at was USD 421.965. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 334,762 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| VTRS - Viatris Inc | HOLD | 0 @ USD 11.94 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 11.94. The average price that VTRS shares were previous bought at was USD 9.92002. The current market price is 20.4% higher than average price they were purchased at. The value of the holding in VTRS has increased by USD 206,295 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.12 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.12. The average price that VYGR shares were previous bought at was USD 3.93356. The current market price is 4.7% higher than average price they were purchased at. The value of the holding in VYGR has fallen by USD 5,251 compared to the previous valuation of Voyager Therapeutics Inc |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 15.54 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 15.54. The average price that WVE shares were previous bought at was USD 8.32371. The current market price is 86.7% higher than average price they were purchased at. The value of the holding in WVE has fallen by USD 94,663 compared to the previous valuation of Wave Life Sciences Ltd |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 43.23 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 43.23. The average price that XENE shares were previous bought at was USD 37.5806. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in XENE has increased by USD 12,494 compared to the previous valuation of Xenon Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 7.01 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 7.01. The average price that XERS shares were previous bought at was USD 6.22689. The current market price is 12.6% higher than average price they were purchased at. The value of the holding in XERS has increased by USD 2,414 compared to the previous valuation of Xeris Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| XNCR - Xencor Inc | HOLD | 0 @ USD 15.69 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 15.69. The average price that XNCR shares were previous bought at was USD 12.5279. The current market price is 25.2% higher than average price they were purchased at. The value of the holding in XNCR has fallen by USD 5,691 compared to the previous valuation of Xencor Inc |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 17.18 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 17.18. The average price that ZLAB shares were previous bought at was USD 31.0921. The current market price is -44.7% lower than average price they were purchased at. The value of the holding in ZLAB has fallen by USD 1,387 compared to the previous valuation of Zai Lab Ltd |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 26.4 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 26.4. The average price that ZYME shares were previous bought at was USD 17.3812. The current market price is 51.9% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 45,428 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | SELL | -425 @ USD 8.69001 | USD -3,693 | The ETF sold 425 shares of FDMT on 2025-12-18. The shares were previously bought for an average price of USD 7.76202. The 4D Molecular Therapeutics Inc shares were sold for 12.0% higher than average price of previous purchases. This sale made a profit of USD 394 The average price that the ETF previously sold FDMT share for is USD 5.55782 so the ETF has sold 425 shares on 2025-12-18 at a higher price than the previous selling average. |